R&D Pipeline

Glenmark’s R&D is committed to identifying products that fulfill unique and unmet medical needs in inflammation disorders, especially in respiratory and dermatology therapies and also oncology.

 


Therapy Molecule Indication MoA/Class
Pre-Clinical Phase 1 Phase 2 a Phase 2 b Phase 3 Approval
Respiratory Ryaltris™ - GSP 301 Steroid + AH Allergic Rhinitis
+
 
Respiratory
Respiratory GBR 310 Biosimilar Asthama,CIU
+
 
Respiratory
Respiratory GSP 304 LAMA COPD
+
 
Respiratory
Immunology GRC 39815 ROR y t Inhibitor COPD
+
 
Immunology